You can help expand this article with text translated from the corresponding article in French. (April 2012) Click [show] for important translation instructions.
View a machine-translated version of the French article.
Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing French Wikipedia article at [[:fr:Pierre Potier]]; see its history for attribution.
You may also add the template {{Translated|fr|Pierre Potier}} to the talk page.
Potier attended the Faculté de pharmacie de Paris, and then the Institut de Chimie des Substances Naturelles (ICSN) in Gif-sur-Yvette. While working at this institution he collaborated with Edgar Lederer, Derek Barton and Guy Ourisson.[1] In 1968, he lost his wife to breast cancer.[2] This pushed him to work on cancer. For two years from July 1994, he was the director general of research and technology at the ministère français de l'Enseignement supérieur et de la Recherche. In 1998, he received the CNRS gold medal.[3] He was president of the Fondation de la maison de la chimie. Potier was an officer of the Légion d'honneur.
Works
His research was orientated towards understanding and imitating natural synthesis occurring in plants so as to produce the active compounds in drugs. In the course of his work he perfected the tubuline test, a simple biological test permitting the rapid detection of anti-tumoral drugs.
Amongst his discoveries are vinorelbine (from the Catharanthus roseus) and docetaxel (from Taxus baccata). Docetaxel commercialised under the name Taxotere has become one of the most prescribed anti-cancer drugs in the world and was the number one source of revenue for the CNRS from patents, until the expiry of its patent. All his life he wanted to prove that public research could and should co-operate with the private sector. Potier was convinced that mutual profit could result from this co-operation.
